PMID: 9174182Jun 1, 1997Paper

Modeling the response of pneumonia to antimicrobial therapy

Antimicrobial Agents and Chemotherapy
J M HyattJ J Schentag

Abstract

The response to antimicrobial therapy in patients with pneumonia was assessed by using a previously developed pneumonia scoring system. Patients from two different clinical trials were evaluated. The first group (n = 22) was treated with cefmenoxime. For these patients, doses were adjusted to achieve an area under the plasma concentration-versus-time curve (AUC) above the MIC of 140 microg x h/ml and pneumonia response scores were evaluated retrospectively. The second group (n = 21) were treated with either ciprofloxacin (CIP) or ceftazidime (TAZ) in a randomized clinical trial. Here, doses were adjusted to achieve AUC from 0 to 24 h/MIC values that were > 250 SIT(-1) x h (estimate of the area under the curve of inverse serum inhibitory titer versus time) and pneumonia response scoring was concurrent. In both studies eradication of the pathogen was determined by serial endotracheal cultures and clinical parameters were scored daily. A decrease in total score was indicative of an improving clinical condition. The percent change in clinical daily score was determined for each day of treatment. The rate of clinical response was determined by linear regression of the percent change in daily clinical score versus time during the cou...Continue Reading

References

Dec 21, 1984·The American Journal of Medicine·J J SchentagJ W Vance
Sep 24, 1983·Lancet·J R Le GallA Alperovitch
Nov 1, 1982·The Journal of Infectious Diseases·A U GerberW A Craig
May 1, 1993·Antimicrobial Agents and Chemotherapy·A ForrestJ J Schentag
Dec 30, 1948·The New England Journal of Medicine·P A TUMULTY, G ZUBROD

❮ Previous
Next ❯

Citations

Feb 2, 2000·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·J M Hyatt, J J Schentag
Oct 2, 2003·The Annals of Pharmacotherapy·Jerome J SchentagAlan Forrest
Nov 30, 2000·Current Infectious Disease Reports·P Ball

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.